January 27, 2016 – CHARLOTTESVILLE, Va. – BrightSpec, Inc. announced today the award of $750,000 Phase II SBIR in funding from the National Science Foundation for pharmaceutical impurities analysis using the BrightSpec millimeter wave FT-MRR spectrometer.
The BrightSpec Fourier transform molecular rotational resonance (FT-MRR) spectrometer enables high resolution chemical analysis of small molecules in a complex mixture, without the need for chromatography. The focus of the new funding grant is to develop automated sampling capabilities for the assessment of mutagenic impurities, as defined by the ICH M7 reference criteria. The new award follows prior awards from the NSF and the US Army that resulted in the launch of the BrightSpec product line.
“With the benefit of input from several pharmaceutical companies, this award advances our work to increase the throughput of pharmaceutical discovery and process development groups.” said Brent Harris, BrightSpec Director of Application Development.
The Small Business Innovation and Research (SBIR) grants are awarded to new companies to drive the commercialization of new technologies with revolutionary potential.
About BrightSpec, Inc
BrightSpec spectrometers deliver direct, quantitative mixture analysis for process R&D laboratories in the chemical manufacturing industry. For more information, please contact Brent Harris, Director of Applications Development or Linda Kidder, Director of Marketing at 434-202-2391, or visit www.brightspec.com.